Novavax (NVAX) announced progress in Q4 advancing its corporate growth strategy through its partnership with Sanofi (SNY). The company has ...

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $9.02 which represents a slight increase of $0.20 or 2.27% from the prior close of $8.82. The stock opened at $8.77 and touched a low of ...

Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone ...

On Tuesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $8.77 which represents a decrease of $-0.30 or -3.31% from the prior close of $9.07. The stock opened at $9.1 and touched a low of ...

Vernon Bernardino, an analyst from H.C. Wainwright, maintained the Buy rating on Novavax (NVAX – Research Report). The associated price target ...

Shares of Novavax Inc. NVAX slid 3.31% to $8.77 Tuesday, on what proved to be an all-around poor trading session for the ...

Novavax Inc. closed $15.04 short of its 52-week high ($23.86), which the company reached on June 6th.

Novavax, Inc. (NASDAQ:NVAX – Free Report) – Equities research analysts at Zacks Research dropped their FY2024 earnings ...

Charles Schwab Investment Management Inc. increased its position in Novavax, Inc. (NASDAQ:NVAX – Free Report) by 16.5% in the ...

Novavax has faced challenges in the past ... which included plans to commercialize a COVID-flu combination vaccine. So far ...